SAB Biotherapeutics price target raised to $14 from $12 at Chardan

Chardan raised the firm’s price target on SAB Biotherapeutics (SABS) to $14 from $12 and keeps a Buy rating on the shares. The company has reported additional data from its Phase I trial of SAB-142 being developed as a treatment for type I diabetes, with the firm saying that the data provide further evidence that SAB-142 has potential to be an effective therapy. The firm also noted a caveat that this data is from a very small number of patients.